4399在线视频免费观看

煙(yan)臺榮昌制(zhi)(zhi)藥(yao)(yao)(yao)股(gu)份有(you)限(xian)(xian)(xian)公(gong)(gong)(gong)司(si)(si)成立(li)于(yu)1993年，公(gong)(gong)(gong)司(si)(si)下設榮昌制(zhi)(zhi)藥(yao)(yao)(yao)（淄博）有(you)限(xian)(xian)(xian)公(gong)(gong)(gong)司(si)(si)、北京榮昌藥(yao)(yao)(yao)物(wu)(wu)研究院、煙(yan)臺立(li)達醫(yi)(yi)藥(yao)(yao)(yao)有(you)限(xian)(xian)(xian)公(gong)(gong)(gong)司(si)(si)、榮昌生(sheng)(sheng)物(wu)(wu)制(zhi)(zhi)藥(yao)(yao)(yao)（煙(yan)臺）有(you)限(xian)(xian)(xian)公(gong)(gong)(gong)司(si)(si)、煙(yan)臺邁(mai)百瑞國際(ji)生(sheng)(sheng)物(wu)(wu)醫(yi)(yi)藥(yao)(yao)(yao)有(you)限(xian)(xian)(xian)公(gong)(gong)(gong)司(si)(si)和(he)煙(yan)臺業達國際(ji)生(sheng)(sheng)物(wu)(wu)醫(yi)(yi)藥(yao)(yao)(yao)創新孵化中(zhong)心(xin)有(you)限(xian)(xian)(xian)公(gong)(gong)(gong)司(si)(si)，榮昌集團已經(jing)發展成為集研發、生(sheng)(sheng)產、銷售為一體，橫跨現代(dai)中(zhong)藥(yao)(yao)(yao)、生(sheng)(sheng)物(wu)(wu)制(zhi)(zhi)藥(yao)(yao)(yao)、生(sheng)(sheng)物(wu)(wu)藥(yao)(yao)(yao)物(wu)(wu)研發生(sheng)(sheng)產外包(bao)、生(sheng)(sheng)物(wu)(wu)醫(yi)(yi)藥(yao)(yao)(yao)企(qi)業和(he)項目孵化四(si)大(da)領(ling)域的現代(dai)化制(zhi)(zhi)藥(yao)(yao)(yao)企(qi)業。

公(gong)司(si)主要從事(shi)中(zhong)(zhong)西(xi)藥、生(sheng)物(wu)新(xin)藥的(de)開發、生(sheng)產和銷售。現(xian)有中(zhong)(zhong)藥、化學藥各類品(pin)種80多個，其中(zhong)(zhong)8個被列為“國(guo)家中(zhong)(zhong)藥保護(hu)品(pin)種”，擁(yong)有13項發明專利，其中(zhong)(zhong)，”肛泰(tai)”及“甜夢(meng)”兩大系列為公(gong)司(si)重點產品(pin)。

公司(si)自1999年進(jin)入(ru)(ru)生(sheng)物(wu)(wu)醫藥(yao)(yao)(yao)創(chuang)新領域，取(qu)得(de)了(le)(le)一(yi)系(xi)列令人矚目(mu)的(de)(de)成績(ji)：2005年，與(yu)留(liu)美博(bo)士團隊成立的(de)(de)合(he)資公司(si)成功研(yan)發(fa)出(chu)了(le)(le)生(sheng)物(wu)(wu)制(zhi)品(pin)抗腫瘤一(yi)類新藥(yao)(yao)(yao)重組人血(xue)(xue)管(guan)內皮抑制(zhi)素”恩度(du)”。該(gai)藥(yao)(yao)(yao)的(de)(de)上市(shi)，標志著(zhu)中(zhong)國(guo)(guo)在(zai)血(xue)(xue)管(guan)抑制(zhi)劑類抗腫瘤藥(yao)(yao)(yao)物(wu)(wu)的(de)(de)研(yan)發(fa)走(zou)在(zai)了(le)(le)世(shi)界(jie)前(qian)列。目(mu)前(qian)，公司(si)共開展了(le)(le)8個生(sheng)物(wu)(wu)一(yi)類新藥(yao)(yao)(yao)的(de)(de)研(yan)發(fa)創(chuang)制(zhi)工作，其(qi)中(zhong)1項(xiang)(xiang)列入(ru)(ru)國(guo)(guo)家(jia)“863”計劃(hua)，6項(xiang)(xiang)進(jin)入(ru)(ru)國(guo)(guo)家(jia)“新藥(yao)(yao)(yao)創(chuang)制(zhi)”重大專項(xiang)(xiang)，目(mu)前(qian)7項(xiang)(xiang)進(jin)入(ru)(ru)臨(lin)(lin)(lin)床或臨(lin)(lin)(lin)床前(qian)研(yan)究；免疫抑制(zhi)劑類基因工程一(yi)類新藥(yao)(yao)(yao)“泰愛”項(xiang)(xiang)目(mu)現已(yi)進(jin)入(ru)(ru)二、三期(qi)臨(lin)(lin)(lin)床研(yan)究。2015年9月(yue)，公司(si)自主研(yan)發(fa)的(de)(de)生(sheng)物(wu)(wu)新藥(yao)(yao)(yao)“RC-48”獲得(de)臨(lin)(lin)(lin)床批(pi)件，是國(guo)(guo)內進(jin)入(ru)(ru)人體臨(lin)(lin)(lin)床試驗(yan)的(de)(de)ADC藥(yao)(yao)(yao)物(wu)(wu)。

2011年公(gong)司(si)與同濟大學、煙(yan)(yan)臺經濟技(ji)術開發(fa)區管委共同建設“生物(wu)新藥創制聯合平(ping)臺及開發(fa)基(ji)地”，在基(ji)因工(gong)程(cheng)藥物(wu)研(yan)發(fa)上進(jin)行產學研(yan)合作。共同出資(zi)成立煙(yan)(yan)臺邁百瑞國際生物(wu)醫藥有(you)限公(gong)司(si)，項目總投資(zi)4.676億(yi)，將建成符合歐美GMP標準的(de)、亞(ya)洲CHO表達系統研(yan)發(fa)、生產基(ji)地。

公司(si)被先后授(shou)予“國家（企(qi)(qi)(qi)(qi)業(ye)）創新(xin)藥(yao)(yao)物孵化(hua)(hua)基地”、“國家綜合性新(xin)藥(yao)(yao)研發技(ji)(ji)術(shu)大(da)平(ping)臺(tai)（山(shan)(shan)(shan)東(dong)）產業(ye)化(hua)(hua)示范(fan)企(qi)(qi)(qi)(qi)業(ye)”、“火炬計劃(hua)重點(dian)高新(xin)技(ji)(ji)術(shu)企(qi)(qi)(qi)(qi)業(ye)”、“山(shan)(shan)(shan)東(dong)省優秀民營科技(ji)(ji)企(qi)(qi)(qi)(qi)業(ye)”、“山(shan)(shan)(shan)東(dong)省高新(xin)技(ji)(ji)術(shu)企(qi)(qi)(qi)(qi)業(ye)”、“山(shan)(shan)(shan)東(dong)省中(zhong)藥(yao)(yao)現代化(hua)(hua)科技(ji)(ji)示范(fan)企(qi)(qi)(qi)(qi)業(ye)” 等稱號(hao)。